Merck reports 2024 sales at $64.2 billion

The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion

Akums reports Q3 FY25 adjusted PAT at Rs. 66.3 Cr

Branded formulation business continues to perform well across domestic and export markets

Hikal Q3 FY25 consolidated revenue recorded at Rs. 448 Cr

The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile

Philogen completes patient enrollment of Phase III FIBROSARC trial in Soft Tissue Sarcoma

These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential

JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%

Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24

Gandhar Oil Refinery (India) Q3 FY25 consolidated revenues reaches Rs. 1,005.3 Cr

Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL

Alkem launches Kojiglo serum to manage facial hyperpigmentation

This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology

Pfizer reports 2024 revenues 7% higher at $63.6 billion

Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion

FDA approves Roche’s Susvimo as the first and only continuous delivery treatment diabetes-related blindness

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)

Hikal appoints Dr. Raghavendar Morthala as Head – CDMO R&T Pharma & Animal Health BU